Beta Lapachone

N/A

Report date: 2025/05/29 20:00:08
NME

Base Information

Drug NameBeta Lapachone
Drug Alias Nameβ Lapachonebeta-lapachonebeta-lapARQ-501SL-11001 +[13] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTranscription factor E2F1 stimulantsNAD-dependent deacetylase sirtuin 1 stimulantsPeroxisome proliferator-activated receptor gamma coactivator 1-alpha stimulants
TargetsTranscription factor E2F1NAD-dependent deacetylase sirtuin 1Peroxisome proliferator-activated receptor gamma coactivator 1-alpha
Therapy Area/IndicationsSolid tumoursObesityMetabolic Syndrome +[11] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSouth Korea
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesArisyn
China Registration ClassN/A

Develop Information

Active CompaniesCurome Biosciences Co Ltd
Inactive CompaniesArqule IncYungjin Pharm Co Ltd
Active IndicationsCholangitis, Sclerosing
Inactive IndicationsSolid tumoursObesityMetabolic Syndrome +[10] 

Other Information

ATC CodeN/A
Related LinksKEGG